These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37209152)

  • 1. In vitro evaluation of anticoagulant therapy management when urgent percutaneous coronary intervention is required in rivaroxaban-treated patients.
    Melek M; Ari H; Ari S; Cilgin MC; Yarar M; Huysal K; Ağca FV; Bozat T
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3221-3232. PubMed ID: 37209152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
    Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
    Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unfractionated Heparin with Sequential Enoxaparin in Patients with Complex Coronary Artery Lesions during Percutaneous Coronary Intervention.
    Li ZZ; Tao Y; Wang S; Yin CQ; Gao YL; Cheng YT; Li Z; Ma CS
    Chin Med J (Engl); 2018 Oct; 131(20):2417-2423. PubMed ID: 30334526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin chains stored during chronic treatment are mobilized by a bolus of unfractionated heparin: insights from the STACKENOX study.
    Bal Dit Sollier C; Berge N; Drouet L
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):779-785. PubMed ID: 26720847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention.
    Huang J; Li N; Li Z; Hou XJ; Li ZZ
    Chin Med J (Engl); 2018 Apr; 131(7):764-769. PubMed ID: 29578118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial.
    Vranckx P; Leebeek FW; Tijssen JG; Koolen J; Stammen F; Herman JP; de Winter RJ; van T Hof AW; Backx B; Lindeboom W; Kim SY; Kirsch B; van Eickels M; Misselwitz F; Verheugt FW
    Thromb Haemost; 2015 Aug; 114(2):258-67. PubMed ID: 25925992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
    Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
    J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
    Sanchez-Pena P; Hulot JS; Urien S; Ankri A; Collet JP; Choussat R; Lechat P; Montalescot G
    Br J Clin Pharmacol; 2005 Oct; 60(4):364-73. PubMed ID: 16187968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: a multicenter open randomized study. Enoxart Study Group.
    Samama CM; Gigou F; Ill P
    Ann Vasc Surg; 1995; 9 Suppl():S45-53. PubMed ID: 8688309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
    Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
    Teng R; Butler K
    J Clin Pharm Ther; 2012 Dec; 37(6):704-11. PubMed ID: 22747575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
    Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
    Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin.
    Silvain J; O'Connor SA; Yan Y; Kerneis M; Hauguel-Moreau M; Zeitouni M; Overtchouk P; Ankri A; Brugier D; Vicaut E; Ecollan P; Galier S; Collet JP; Montalescot G;
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):503-511. PubMed ID: 30144017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.
    Kaeberich A; Reindl I; Raaz U; Maegdefessel L; Vogt A; Linde T; Steinseifer U; Perzborn E; Hauroeder B; Buerke M; Werdan K; Schlitt A
    J Thromb Thrombolysis; 2011 Nov; 32(4):417-25. PubMed ID: 21773837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
    Naumnik B; Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.